by Stephen Pincock, Ted Agres and Ivan Oransky
FEATURE	The Year That Was Foundations, regulations, and approvals were the industry and policy highlights of 2005 The Scientist 2005, 19(23):18 Published   5 December 2005

In a year in which several Big Pharma players felt pain as the Vioxx imbroglio settled out – take August's $253 million settlement against Merck, for example – news in funding, policy, and strategy, from government agencies to biotechs, suggests that the industry is still as robust as ever. Here's our unofficial Top 10 list of developments, in no particular order.

(continued >>)

To continue reading this full article, you must be a subscriber to The Scientist.

You are only a few minutes away from unlimited access.

If you already have an online subscription, please Log-In Now.
New to The Scientist? Register to get access to a selection of our content, interactive features and useful tools free without a subscription.

Subscribe to The Scientist to get unlimited access to our premium content

Get unlimited access to this article and over 20 years of The Scientist archives. You won’t miss a word – all for as little as $4.95.  Subscribe now.

The Scientist offers site licenses to institutions and organizations. Recommend us to your librarian and get online access through your place or work or study.